Want to see GLMD full AI Analyst Report?
Total Valuation
Galmed Pharmaceuticals has a market cap or net worth of $4.41M. The enterprise value is -$11.64.
Market Cap$4.41M
Enterprise Value-$11.64
Share Statistics
Galmed Pharmaceuticals has 8,262,953 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding8,262,953
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Galmed Pharmaceuticals’s return on equity (ROE) is -0.65 and return on invested capital (ROIC) is -53.92%.
Return on Equity (ROE)-0.65
Return on Assets (ROA)-0.55
Return on Invested Capital (ROIC)-53.92%
Return on Capital Employed (ROCE)-0.54
Revenue Per Employee0.00
Profits Per Employee-1.72M
Employee Count6
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Galmed Pharmaceuticals is ―. Galmed Pharmaceuticals’s PEG ratio is 0.00446.
PE Ratio―
PS Ratio0.00
PB Ratio0.21
Price to Fair Value0.21
Price to FCF-0.51
Price to Operating Cash Flow-0.46
PEG Ratio0.00446
Income Statement
In the last 12 months, Galmed Pharmaceuticals had revenue of 0.00 and earned -10.31M in profits. Earnings per share was -2.39.
Revenue0.00
Gross Profit0.00
Operating Income-8.51M
Pretax Income-10.31M
Net Income-10.31M
EBITDA-10.31M
Earnings Per Share (EPS)-2.39
Cash Flow
In the last 12 months, operating cash flow was -7.68M and capital expenditures 0.00, giving a free cash flow of -7.68M billion.
Operating Cash Flow-7.68M
Free Cash Flow-7.68M
Free Cash Flow per Share-0.93
Dividends & Yields
Galmed Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.09
52-Week Price Change-66.92%
50-Day Moving Average0.58
200-Day Moving Average0.77
Relative Strength Index (RSI)43.38
Average Volume (3m)84.25K
Important Dates
Galmed Pharmaceuticals upcoming earnings date is May 19, 2027, Before Open (Confirmed).
Last Earnings DateJul 30, 2026
Next Earnings DateMay 19, 2027
Ex-Dividend Date―
Financial Position
Galmed Pharmaceuticals as a current ratio of 6.55, with Debt / Equity ratio of 0.00%
Current Ratio6.55
Quick Ratio6.55
Debt to Market Cap0.00
Net Debt to EBITDA0.39
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Galmed Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Galmed Pharmaceuticals EV to EBITDA ratio is 0.07, with an EV/FCF ratio of 0.12.
EV to Sales0.00
EV to EBITDA0.07
EV to Free Cash Flow0.12
EV to Operating Cash Flow0.12
Balance Sheet
Galmed Pharmaceuticals has $15.45M in cash and marketable securities with $0.00 in debt, giving a net cash position of $15.45M billion.
Cash & Marketable Securities$15.45M
Total Debt$0.00
Net Cash$15.45M
Net Cash Per Share$1.87
Tangible Book Value Per Share$3.66
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Galmed Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast71.38%